13
HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info Section 3: Introduction to ARV Therapy HIV i-Base • STEP • EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

Embed Size (px)

Citation preview

Page 1: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

Section 3: Introduction to ARV Therapy

HIV i-Base • STEP • EATG

HIV Training for Advocates

Page 2: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

• HIV is continually reproducing - an it uses CD4 cells as factories to produce more virus.

• The drugs work at different parts of the HIV lifecycle

• Available drugs work in one of four ways:

i) reverse transcriptase inhibitors (RTIs, nukes)

ii) NNRTIs - non-nukes

iii) protease inhibitors (PIs)

iv) entry inhibitors (T-20)

Combination therapy

Page 3: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

HIV lifecycleHIV lifecycleprotease inhibitorsentry inhibitorsnukes &non-nukes(NNRTIs)HIV virusCD4 cellHIV uses CD4 cells as factories to make hundreds of copies of itself. Different drugs work at different stages of the HIV life cycle.

Page 4: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

1. There are now approx 20 approved anti-HIV drugs and more in development (see page 16 of the i-Base guide)

2. Some are more potent than others

3. A few cannot be used together (ie d4T and AZT)

4. Recent studies and guidelines recommend using two RTIs and either one NNRTI or one PI-based combination as being most effective:

i) AZT / 3TC / efavirenz

ii) AZT / 3TC / lopinavir/r (Kaletra)

5. BUT many other combinations are better for some people: - every drug has different advantages and disadvantages, and newer drugs are being used as first line therapy

Choice of drugs

Page 5: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

• HIV treatment is different to other medications

• Weak treatment (less than 3 drugs) or missing doses (even one dose a week) will lead to resistance, and the combination will fail

• Once resistance develops it never reverses

• Resistance will make the next combination less likely to succeed - because there is cross-resistance between most drugs in each class

How to get treatment right

Page 6: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

• When HIV reproduces - it makes mistakes - so new virus is not exactly the same

• Most of these changes do not matter, but some will stop HIV drugs from working

• Resistance only develops when you are taking treatment with a detectable viral load

• Main cause of resistance is poor adherence

Resistance

Page 7: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

• A ‘little’ HIV treatment is very dangerous

• Treatment needs to be ‘all or nothing’

• Missing doses (even one dose a week) can lead to resistance if you do this regularly

• This is because you need to keep levels of each drug in your combination above a minimum level

• Once you start treatment, getting a strategy to never miss a dose is the most important thing you have to do in your life. Especially critical for first months.

Adherence

Page 8: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

C Max

Drug concentration

0

dose

Time

After taking a drug, levels peak quickly and then slowly drop as the drug is eliminated - every drug has its own drug absorption curves

T Max

AUC = Area Under Curve

T 1/2

Drug absorption

Page 9: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

dose

C Max

0

dose dose

Each dose taken on time makes sure that you keep above a mimimum level

Drug concentration

Time

C Min or C tough

Drug absorption.2

Page 10: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

dose

Increased risk of side effects

0

Increased risk of resistance

dose dose dose

Taking drugs at the exact time makes sure that you keep above a mimimum level

Drug levels and resistance.1

MEC(Minimum Effective Concentration)

Drug concentration

Page 11: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

Accuracy of your dosing will keep you out of the risk zone for resistance

Increased risk of side effects

MEC(Minimum Effective Concentration)

0

Increased risk of resistance

dose Misseddose

dosedoseLatedose

Drug levels and resistance.2

Drug concentration

Page 12: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

• Be an active patient

• Nearly always a choice in every situation - combination therapy is not ‘fixed’ but very flexible

• Effective treatment includes Quality of Life

• Research alternatives

• Follow research for new information (ie lipodystophy)

Side Effects

Page 13: HIV i-Base: Training for Advocates, 10/2004 Section 3: Introduction to ARV Therapy HIV i-Base STEP EATG HIV Training for Advocates

HIV i-Base: Training for Advocates, 10/2004 www.i-Base.info

Focus of huge quantity of research:

- New drugs

- New targets

- New strategies - treatment interruptions

- boosted-PI monotherapy

- boosting immune responses

- individualising treatment (IQ etc)

Future development